|
| Interactions: | Acenocoumarol Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Acenocoumarol should be discontinued prior to the initiation of therapy with LMWH sod.salt . If this is not possible, patients receiving LMWH sod.salt and Acenocoumarol concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time.
Diclofenac Preps. Adverse Effect: An increased risk of bleeding and of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving LMWH sod.salt and Diclofenac Preps concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time. In patients requiring analgesia without antiinflammatory action, acetaminophen or a narcotic analgesic would be preferable.
Flurbiprofen Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Flurbiprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy.
IbuprofenAdverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Ibuprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
IndomethacinAdverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Indomethacin concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Ketoprofen
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Ketoprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Ketorolac Adverse Effect: An increased risk of bleeding and of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Ketorolac concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time. In patients requiring analgesia without antiinflammatory action, acetaminophen or a narcotic analgesic would be preferable.
Mefenamic Acid Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Meloxicam Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Mesalazine - Antisecr. Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed
Clinical Management: Mesalazine - Antisecr should be discontinued prior to the initiation of therapy with LMWH sod.salt or heparinoid. If this is not possible, patients receiving LMWH sod.salt or heparinoid and Mesalazine - Antisecr concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin or heparinoid therapy. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time.
Nabumetone Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Naproxen Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Naproxen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Nimesulide Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Nimesulide concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Oxyphenbutazone Adverse Effect: An increased risk of bleeding and of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving LMWH sod.salt and Oxyphenbutazone concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time. In patients requiring analgesia without antiinflammatory action, acetaminophen or a narcotic analgesic would be preferable.
Phenylbutazone Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Piroxicam Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Tenoxicam Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Warfarin Adverse Effect: An increased risk of bleeding and of hematoma when neuraxial anesthesia is employed Clinical Management: Warfarin should be discontinued prior to the initiation of therapy with LMWH sod.salt . If this is not possible, patients receiving LMWH sod.salt and Warfarin concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. Clinicians should be aware that the increased risk of bleeding with this combination will not be fully reflected by the partial thromboplastin time. |
|
|